P-005 YI Early Dose-escalation of Infliximab for Colectomy Avoidance in Anti-TNF Naïve UC Patients Hospitalized with Severe Colitis; A Tertiary-care Centerʼs Experience

Background: Biologics used to treat ulcerative colitis (UC) may lose their effect over time, requiring patients to undergo dose escalation or treatment switching, and systematic literature reviews of realworld evidence on these topics are lacking. Aim: To summarize the occurrence and outcomes of dose escalation and treatment switching in UC patients in real-world evidence. Methods: Studies were searched through MEDLINE, MEDLINE IN PROCESS, Embase and Cochrane (2006-2017) as well as proceedings from three major scientific meetings. Results: In total, 41 studies were included in the review among which 35 covered dose escalation and 12 covered treatment switching of biologics. Tumor necrosis factor antagonist (anti-TNF) escalation for all patients included at induction ranged from 5% (6 months) to 50% (median 0.67 years) and 15.2% to 70.8% (8 weeks) for anti-TNF induction responders. Mean/median time to dose escalation on anti-TNF ranged from 1.84 to 11 months. The most common switching pattern, infliximab ! adalimumab, occurred in 3.8% (median 5.6 years) to 25.5% (mean 3.3 years) of patients. Conclusions: Dose escalation and treatment switching of biologics may be considered as indicators of suboptimal therapy suggesting a lack of long-term remission and response under current therapies.

show abstract

Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence

Gemayel¹,

Rizzello²,

Atanasov³

et al. 2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P-005 YI Early Dose-escalation of Infliximab for Colectomy Avoidance in Anti-TNF Naïve UC Patients Hospitalized with Severe Colitis; A Tertiary-care Centerʼs Experience

Cited by 1 publication

References 0 publications

Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence

Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence

Contact Info

Product

Resources

About